Abstract
The role of Sx of the primary tumor remains highly debatable in de novo stage IV BC. We aimed to assess Overall Survival (OS) among de novo metastatic BC pts who underwent Sx of the primary tumor ≤9 months (m) after diagnosis vs pts who did not, adjusting for prognostic factors.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have